RJA
PTX

Raymond James & Associates’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Raymond James & Associates’s Portfolio PTX Stock Details PTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,325
Closed -$249K – 2489
2015
Q1 		$249K Buy
+2,325
New +$222K ﹤0.01% 2266

Other funds holding PTX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
RCMC
RK Capital Management (Colorado) Denver, Colorado $324K AUM 47.52% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Raymond James & Associates's PTX Position: Q2 2015 in Review

Raymond James & Associates sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q2 2015, closing a stake of 2,325 shares — an estimated $249K sold.

Raymond James & Associates first reported a position in PTX in Q1 2015 and held it in 1 quarter. The position peaked at $249K in Q1 2015. 114 funds tracked by Wall St. Rank hold PTX as of Q2 2015.

  • Raymond James & Associates reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q2 2015 after selling out during the quarter.
  • Raymond James & Associates sold 2,325 Pernix Therapeutics Holdings, Inc. shares in Q2 2015, an estimated $249K.
  • Raymond James & Associates first reported a position in Pernix Therapeutics Holdings, Inc. in Q1 2015 and held it in 1 quarter.
  • Raymond James & Associates's Pernix Therapeutics Holdings, Inc. position peaked at $249K in Q1 2015.
  • 114 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q2 2015.

Based on Raymond James & Associates's 13F filing for Q2 2015, filed 13 Aug 2015.